APOE and atherosclerosis: Pharmacological inhibition of S100A12 using Quinolone 3-carboxamide (ABR-215757), which binds S100A12 and prevents activation of RAGE in vitro, also reduces atherosclerosis and vascular calcification in ApoE null mice with transgenic S100A12 expression, suggesting that that S100A12 is a potential pharmacological target (31, 35).